Literature DB >> 9405338

Immune versus natural selection: antibody aldolases with enzymic rates but broader scope.

C F Barbas1, A Heine, G Zhong, T Hoffmann, S Gramatikova, R Björnestedt, B List, J Anderson, E A Stura, I A Wilson, R A Lerner.   

Abstract

Structural and mechanistic studies show that when the selection criteria of the immune system are changed, catalytic antibodies that have the efficiency of natural enzymes evolve, but the catalytic antibodies are much more accepting of a wide range of substrates. The catalytic antibodies were prepared by reactive immunization, a process whereby the selection criteria of the immune system are changed from simple binding to chemical reactivity. This process yielded aldolase catalytic antibodies that approximated the rate acceleration of the natural enzyme used in glycolysis. Unlike the natural enzyme, however, the antibody aldolases catalyzed a variety of aldol reactions and decarboxylations. The crystal structure of one of these antibodies identified the reactive lysine residue that was selected in the immunization process. This lysine is deeply buried in a hydrophobic pocket at the base of the binding site, thereby accounting for its perturbed pKa.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9405338     DOI: 10.1126/science.278.5346.2085

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  61 in total

1.  Catalytic and binding poly-reactivities shared by two unrelated proteins: The potential role of promiscuity in enzyme evolution.

Authors:  L C James; D S Tawfik
Journal:  Protein Sci       Date:  2001-12       Impact factor: 6.725

2.  Synthesis of an organoinsulin molecule that can be activated by antibody catalysis.

Authors:  D S Worrall; J E McDunn; B List; D Reichart; A Hevener; T Gustafson; C F Barbas; R A Lerner; J M Olefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

3.  Multiple event activation of a generic prodrug trigger by antibody catalysis.

Authors:  D Shabat; C Rader; B List; R A Lerner; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

4.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

5.  Covalent intermediate trapped in 2-keto-3-deoxy-6- phosphogluconate (KDPG) aldolase structure at 1.95-A resolution.

Authors:  J Allard; P Grochulski; J Sygusch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

6.  New mechanistic studies on the proline-catalyzed aldol reaction.

Authors:  Benjamin List; Linh Hoang; Harry J Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-08       Impact factor: 11.205

7.  Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab.

Authors:  Subhash C Sinha; Lian-Sheng Li; Gregory P Miller; Shantanu Dutta; Christoph Rader; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

8.  Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics.

Authors:  Ulrich Wuellner; Julia I Gavrilyuk; Carlos F Barbas
Journal:  Angew Chem Int Ed Engl       Date:  2010-08-09       Impact factor: 15.336

9.  Chemically Programmable and Switchable CAR-T Therapy.

Authors:  Junpeng Qi; Kohei Tsuji; David Hymel; Terrence R Burke; Michael Hudecek; Christoph Rader; Haiyong Peng
Journal:  Angew Chem Int Ed Engl       Date:  2020-05-18       Impact factor: 15.336

10.  The Positively Charged Active Site of the Bacterial Toxin RelE Causes a Large Shift in the General Base pKa.

Authors:  David A Hiller; Brian F Dunican; Sunitha Nallur; Nan-Sheng Li; Joseph A Piccirilli; Scott A Strobel
Journal:  Biochemistry       Date:  2020-04-24       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.